FindTrial
Sign In

Interaction of nonalcoholic fatty liver disease with drug-induced liver injury: A real world study from a specialized liver disease center in China

Objective Study on TCM Constitution of Chronic Liver Diseases such as Hepatitis B Based on Metabolomics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056314
Enrollment
Unknown
Registered
2022-02-03
Start date
2022-01-21
Completion date
Unknown
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease with drug-induced liver injury

Interventions

Nonalcoholic fatty liver disease with drug-induced liver injury group:None
Nonalcoholic fatty liver disease without drug-induced liver injury group:None

Sponsors

The Fifth Medical Center of PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients had histological evidence of NAFLD

Exclusion criteria

Exclusion criteria: 1. Alcohol consumption of more than 20 g per day for at least 3 consecutive months during the previous 5 years; 2. With positive anti-hepatitis B core IgM, hepatitis B virus (HBV) DNA, anti-hepatitis A virus IgM, anti-hepatitis E virus IgM and anti-hepatitis E virus IgG, or with non-hepatitis virus infection, or other liver diseases.

Design outcomes

Primary

MeasureTime frame
Blood routine index;Blood biochemical indexes;Body Mass Index (BMI);—

Countries

China

Contacts

Public ContactWang Ruililn

The Fifth Medical Center of PLA General Hospital

WRL7905@163.com+86 13811050593

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026